Samsung Biologics Acquires Entire 2.8 Trillion KRW Stake in Epis
[Asia Economy Reporter Myung-hwan Lee] Samsung Biologics announced on the 28th that it will purchase all shares of Samsung Bioepis worth 2.8 trillion KRW held by its US partner Biogen.
Hot Picks Today
Cerebras Soars 70% on IPO Debut: Is Nvidia's Reign Ending as a New AI Semiconductor Power Emerges?
- [Breaking] Debris from Namuho Spacecraft Arrives in Korea... "Detailed Analysis Planned"
- "Multi-Million Won Bonuses, Life Is Sweet"—Even Employee Reactions... SK hynix Overtakes Samsung to Claim No. 1 Spot
- "It Costs 100,000 Won for Two Hours"...No Place for Kids to Play if Parents Can't Afford It
- Japanese Teacher Dismissed for Obscene Acts Involving Third-Grade Girl's Water Bottle
Samsung Biologics will acquire all 10,341,852 shares held by Biogen for 2.7655 trillion KRW. A Samsung Biologics official explained that the purpose of the stock acquisition is to "strengthen global business competitiveness through enhancing biopharmaceutical development capabilities." Regarding funding for the acquisition, the official stated, "We will raise new funds through internal resources and capital increase, among other methods."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
